Pogostol is an oxygenated sesquiterpene best known as a recurring patchouli-oil constituent rather than as a mainstream standalone fragrance chemical. The public evidence base is strongest for identity and repeated occurrence in patchouli and a smaller number of other essential oils, with only limited direct constituent-level pharmacology available. AromaForge should treat pogostol as a patchouli-linked chemistry marker with one notable anti-emetic screening signal and otherwise substantial evidence gaps around isolated mechanisms, human data, and dedicated safety work.
Aroma and practical use
- Use the recorded patchouli-like, woody, earthy, sesquiterpenic descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 1999 Phytomedicine paper reported that pogostol was among isolated constituents from the n-hexane extract of Pogostemon cablin that exhibited anti-emetic effects in copper-sulfate-induced emesis in young chicks.
A 1999 Phytomedicine paper reported that pogostol was among isolated constituents from the n-hexane extract of Pogostemon cablin that exhibited anti-emetic effects in copper-sulfate-induced emesis in young chicks.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2012 quantitative patchouli-oil evaluation identified pogostol as one of the major compounds across patchouli oils obtained from different source materials and processing conditions.
A 2012 quantitative patchouli-oil evaluation identified pogostol as one of the major compounds across patchouli oils obtained from different source materials and processing conditions.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2013 Curcuma wenyujin oil study described pogostol as one of the representative ingredients of the Wen-yu-jin oil chemotype, indicating that its occurrence is not limited to patchouli alone.
A 2013 Curcuma wenyujin oil study described pogostol as one of the representative ingredients of the Wen-yu-jin oil chemotype, indicating that its occurrence is not limited to patchouli alone.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No human safety study, authoritative constituent-specific dermal limit, or dedicated fragrance-safety monograph for isolated pogostol was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
The reviewed evidence is too thin to support wellness-style or therapeutic safety claims for isolated pogostol.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
no_direct_constituent_specific_mechanism_verified
No direct mechanistic study on isolated pogostol was verified in this pass; the available constituent-level evidence is mainly identity, occurrence, and one screening-style anti-emetic report rather than pathway work.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- Direct constituent-specific mechanism studies for pogostol were not verified.
- No human clinical data for isolated pogostol were located.
- Public constituent-specific dermal, inhalation, and repeated-dose safety evidence remains sparse.
- No IFRA, RIFM, Tisserand & Young, or EU Annex III dermal limit or sensitization determination was found for pogostol as of 2026-07-13 verification pass; the previous dermal_limit_pct value of 20 and sensitizing:true had no locatable citation and were corrected to null/false.
- Second-pass verification (2026-07-13) confirmed, via the full TGSC record (a genuinely different angle than the earlier general Tisserand-site search), that pogostol has no RIFM safety assessment and no IFRA Code of Practice usage-level entry at all -- TGSC explicitly flags it as 'not for fragrance use' / 'not for flavor use', i.e., simply unregistered for those uses rather than actively restricted. dermal_limit_pct and sensitizing remain null/false by absence of data, not by a confirmed negative finding.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.